DBV Technologies | DBVT - 税前利润

股票价格
19.79
每天变化
-0.20 -1.00%
每月一次
-7.52%
每年
101.32%
Q2 预测
19.41


金融业
股票价格
USD
资产
USD 233.72M
现金及等价物
USD 194.17M
流动资产
USD 212.94M
流动负债
USD 58.03M
债务
USD 8.59M
股息收益率
USD 0
EBIT
USD -34.28M
EBITDA
USD -33.49M
员工
USD 104
EPS每股收益
USD -0.24
股本和储备
USD 168.77M
销售毛利
USD 2.77M
债务利息支出
USD 461K
利息收入
USD -0.32
贷款资金
USD 0
市值
USD 766M
净收入
USD -33.16M
营业费用
USD 37.05M
营业利润
USD -34.28M
普通股股本
USD 136.82M
税前利润
USD -33.16M
销售收入
USD 2.77M
销售和管理费用
USD 3.63M
贸易债权人
USD 39.82M
应收帐款人
USD 15.97M


税前利润 更改 日
Acadia Pharmaceuticals USD 3.98M 22.34M 2026-03
Alnylam Pharmaceuticals USD 221.65M 60.52M 2026-03
Amarin USD -852K 7.26M 2025-12
BioCryst Pharmaceuticals USD 248.02M 235.89M 2025-12
BioMarin Pharmaceutical USD 141.2M 168.36M 2026-03
DBV Technologies USD -33.16M 8.6M 2025-09
Esperion Therapeutics USD 63.67M 95M 2025-12
Galectin Therapeutics USD -12.37M 880K 2024-06
Halozyme Therapeutics USD 218.96M 14.02M 2025-09
Incyte USD 343.6M 46.34M 2026-03
Insmed USD -162.1M 164.84M 2026-03
Ionis Pharmaceuticals USD -93M 135M 2026-03
Neurocrine Biosciences USD 246.8M 7.4M 2026-03
PTC Therapeutics USD -2.46M 136.62M 2026-03
Sarepta Therapeutics USD 343.17M 750.85M 2026-03
Ultragenyx Pharmaceutical USD -184M 56M 2026-03
United Therapeutics USD 444M 6M 2025-12